Tapering Sertraline and Managing Emotional Blunting and Weight Gain
For patients at low risk of withdrawal symptoms, taper sertraline by reducing the dose by 25-50% every 2 weeks (e.g., 100 mg → 50 mg → 25 mg → stop over 4-6 weeks); for those at higher risk or with prior difficulty stopping, use much smaller decrements over many weeks to months, potentially down to 1 mg doses using compounded formulations. 1, 2
Sertraline Tapering Strategy
The FDA label emphasizes that abrupt discontinuation can cause withdrawal symptoms, so medication should be tapered "as rapidly as is feasible" while recognizing discontinuation risks 1. The specific approach depends on your withdrawal risk:
Low-risk patients (shorter duration of therapy, no prior withdrawal issues):
- Reduce dose by 25-50% every 2-4 weeks
- Example: 100 mg → 50 mg (2 weeks) → 25 mg (2 weeks) → stop
- Total duration: 4-6 weeks 2
High-risk patients (longer therapy duration, history of withdrawal symptoms, duloxetine/venlafaxine/paroxetine users):
- Use much smaller decrements (10-25% reductions)
- Extend tapering over many weeks to months
- May require compounded "mini doses" down to 1 mg sertraline
- Monitor closely for withdrawal symptoms: anxiety, agitation, insomnia, irritability 1, 2
Common pitfall: Withdrawal symptoms from sertraline are more likely with longer treatment duration. Don't rush the taper if the patient has been on sertraline for years.
Antidepressants for Emotional Blunting and Weight Gain
Switch to bupropion, which causes modest weight loss and has the lowest rate of emotional blunting (31.82%) among antidepressants studied. 3, 4
Evidence on Emotional Blunting
Emotional blunting affects 40-60% of patients on SSRIs/SNRIs and is a leading cause of medication discontinuation 3. In a recent cross-sectional study:
- Duloxetine had the highest rate (73.68%)
- Bupropion had the lowest rate (31.82%)
- Nearly 40% of patients considered stopping antidepressants due to emotional numbing 3
Evidence on Weight Effects
Among second-generation antidepressants 4:
- Bupropion: Modest weight loss (best option)
- Mirtazapine and paroxetine: Modest weight gain (avoid)
- Most other SSRIs/SNRIs: Weight neutral, but individual variation occurs
Switching strategy: When transitioning from sertraline to bupropion, you can either cross-taper (gradually reduce sertraline while introducing bupropion) or complete the sertraline taper first, then start bupropion. Cross-tapering is generally preferred to maintain antidepressant coverage.
Adding Aripiprazole (Abilify)
Yes, you can add low-dose aripiprazole (2.5-12 mg/day) to sertraline for augmentation, which is supported by FDA approval and multiple randomized controlled trials showing superior efficacy compared to sertraline alone. 5, 6, 7
Efficacy Evidence
Two high-quality randomized controlled trials demonstrate:
A 2018 double-blind RCT (n=412) showed aripiprazole 3-12 mg/day plus sertraline 100 mg/day produced significantly greater improvement in depression scores than sertraline alone (MADRS change: -9.2 vs -7.2, p=0.0070) 7
A 2011 trial showed adjunctive aripiprazole 2.5 mg/day with sertraline 50 mg/day improved depression scores at weeks 1,2, and 4, with particular benefit for work/social functioning 6
The 2023 American College of Physicians guideline notes that augmentation with aripiprazole showed higher remission rates (55.4%) compared to bupropion augmentation (34.0%) in one trial, though this was rated as high risk of bias 8.
Aripiprazole Side Effects
Common side effects (≥10% incidence) 5:
- Akathisia (inner restlessness/need to move): 12.9% vs 3.4% placebo
- Nasopharyngitis
- Weight gain (though lower risk than other antipsychotics)
- Nausea, insomnia, anxiety
Serious but rare side effects 5:
- Metabolic effects: High blood sugar/diabetes, increased cholesterol/triglycerides (monitor fasting glucose and lipids)
- Movement disorders: Tardive dyskinesia (may be permanent), neuroleptic malignant syndrome (rare but life-threatening)
- Cardiovascular: Orthostatic hypotension (monitor blood pressure, especially when standing)
- Behavioral: Unusual urges (gambling, compulsive eating, shopping, sexual urges)
- Falls risk due to sedation and orthostatic hypotension
Critical monitoring: Check fasting glucose, lipids, and weight at baseline and regularly during treatment. Screen for movement disorders and akathisia at each visit 5.
Drug Interactions
The FDA label notes no dosage adjustment needed when aripiprazole is combined with sertraline 5. However, if you're also on strong CYP3A4 inhibitors or CYP2D6 inhibitors, aripiprazole dose should be reduced 5.
Clinical Algorithm
If continuing sertraline + adding aripiprazole: Start aripiprazole 2.5-5 mg/day, can increase to 12 mg/day based on response. Monitor for akathisia and metabolic effects 6, 7
If switching due to emotional blunting/weight gain: Taper sertraline as outlined above while cross-tapering to bupropion (start 150 mg/day, can increase to 300-450 mg/day) 3, 4
If inadequate response after 8-12 weeks on sertraline alone: Consider augmentation with low-dose aripiprazole rather than switching, as this has stronger evidence for treatment-resistant depression 8, 7
Important caveat: The studies showing benefit of aripiprazole augmentation used doses as low as 2.5 mg/day with good efficacy and tolerability 6. Starting low minimizes side effects, particularly akathisia, which occurred in 12.9% at higher doses 7.